Health Condition 1: null- Computer Vision Syndrome
Conditions
Interventions
Intervention1: Mahatriphaladi Ghritam
Anu Tailam: Mahatriphala Ghritam- Tarpana (local eye treatment) for 3 days at the interval of 15 days.
Mahatriphaladi Ghritam- 5 ml orally twice a day for 42 day
Sponsors
Centrral Council for Research in Ayurvedic Sciences
Eligibility
Inclusion criteria
Inclusion criteria: i) Patients of either sex aged between 18 to 35 years ii) Patients having minimum three symptoms of Computer Vision Syndrome (Eye strain and fatigue,Headache, blurred vision, Dry and irritated eyes, Neck and shoulder pain, Double vision,Redness of eyes, Burning eyes, excessive tearing and photophobia) iii) Minimum 3 hours daily exposure to any type of Video Display Terminals like Desktop, Laptop or both iv) Minimum 1 year exposure to any type of above mentioned VDTs v) Willing patients with informed consent obtained.
Exclusion criteria
Exclusion criteria: i) Age less than 18 years and more than 35 years ii) Presence of signs and symptoms due to direct physiological effects of substance (medication, drug abuse) or presence of any general health problems (like Hypothyroidism) iii) Presence of any infectious conditions of the eye, Cataract, Glaucoma, stye, any fundus pathology. iv) Patients having Cervical spondylosis or spasm of trapezius muscle. v) History of any surgical intervention with reference to the eye vi) Patient with h/o Migraine vii) Patients with h/o Hypertension or Diabetes Mellitus viii) Patients with evidence of malignancy. ix) Patients on prolonged ( 6 weeks) medication withcorticosteroids, antidepressants, anticholinergics, oral Contraceptive pills, etc.or any other drugs that may have an influence on the outcome of the study. x) Patients with major systemic illness xi) Patients with concurrent serious hepatic disorder defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) 2 times upper normal limit) or Renal Disorders (defined as S. Creatinine1.2mg/dL), Known case of Pulmonary Dysfunction (uncontrolled Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease [COPD]), or any other condition that may jeopardize the study. xii) Smokers/ Alcoholics and/or drug abuser xiii) H/o hypersensitivity to any of the trial drug or their ingredients xiv) Pregnant / lactating woman. xv) Patients who have completed participation in any other clinical trial during the past six (06) months xvi) Any other condition which the Principal Investigator thinks may jeopardize the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in signs and symptoms of CVSTimepoint: Reduction in signs and symptoms of Computer Vision Syndrome at baseline and at the end of42nd Day. | — |
Secondary
| Measure | Time frame |
|---|---|
| NILTimepoint: NIL | — |
Countries
India
Contacts
Public ContactDr Rakhi Mehra
Ayurveda Central Research Institute
Outcome results
None listed